We previously demonstrated a direct link between TROP2 expression and ERK1/2 signaling pathway, so we further investigated whether down-regulation of TROP2 enhances cisplatin sensitivity of cervical cancer cells was due to the inactivation of ERK signaling pathway. This evidence concerns the gene TACSTD2 and cervical cancer.